5.7 C
New York
Monday, January 30, 2023

There’s No Getting Around Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Success

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Vertex Pharmaceuticals Incorporated (VRTX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.47, or -0.15%, to $320.29. The Vertex Pharmaceuticals Incorporated has recorded 218,654 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Vertex to Participate in Upcoming Investor Conferences.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Stocks Info

VRTX belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $320.76 and fluctuated between $321.52 as its day high and $315.18 as its day low. The current market capitalization of Vertex Pharmaceuticals Incorporated is $83.72B. A total of 1.55 million shares were traded on the day, compared to an average of 1.49M shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, VRTX has seen 2 BUY and 19 SELL insider trades, representing the acquisition of 6,597 and the disposition of 4,837 shares. Over the last 12 months, there were 58 BUYs and 268 SELLs from insiders. Insiders purchased 489,667 shares during that period but sold 435,182.

In the most recent transaction, ALTSHULER DAVID sold 34 shares of VRTX for 308.61 per share on Nov 15. After the transaction, the EVP, Global Research and CSO now owns 36,077 company shares. In a previous transaction on Nov 07, ALTSHULER DAVID sold 1,303 shares at 303.04 per share. VRTX shares that EVP, Global Research and CSO owns now total 36,077.

Among the insiders who sold shares, Sanna Bastiano disposed of 320 shares on Nov 02 at a per-share price of $312.64. This resulted in the EVP, Cell & Genetic Therapies holding 38,104 shares of VRTX after the transaction. In another insider transaction, Bhatia Sangeeta N. sold 621 shares at $310.00 per share on Oct 24. Company shares held by the Director now total 4,040.


Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. VRTX’s most recent ex-dividend date was when it declared a $0.40 quarterly dividend that was paid in cash on 3/13/2013.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for VRTX in the last 3 months, the mean price target is $327.63 with high estimates of $440.00 and low estimates of $280.00. In terms of 52-week highs and lows, VRTX has a high of $323.61 and a low of $194.10.

As of this writing, VRTX has an earnings estimate of $3.39 per share for the current quarter. EPS was calculated based on a consensus of 20 estimates, with a high estimate of $3.82 per share and a lower estimate of $2.5. The company reported an EPS of $3.6 in the last quarter, which was 3.40% higher than expectations of $3.48.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 28 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRTX is Sell with a score of 4.30. A total of 16 analysts rated the stock as Buy while 3 rated it as Overweight while 9 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles